In Vitro Activity of Tigecycline in the Era of NDM-1
Dorairajan Sureshkumar, Ram Gopalakrishnan and M. A. Thirunarayan
DOI : 10.3844/ajmsp.2012.34.36
Current Research in Microbiology
Volume 3, Issue 2
In the current era of New Delhi Metallo-betalactamase-1 (NDM-1) infections and a dry antibiotic pipeline, managing infections caused by Multi-Drug Resistant Gram-Negative Bacterial infections (MDR-GNBs) presents a great challenge to physicians in the developing world. Tigecycline, a broad spectrum glycylcycline is a one among the few treatment options against MDR-GNBs. However it has been studied mostly in the western world, where the prevalence of MDR-GNB infections is less than the developing world. In this study, we report the in vitro activities of tigecycline and selected antimicrobials against gram-negative bacterial isolates. We evaluated the in vitro activity of tigecycline against 80 gram-negative bacterial isolates and compared its susceptibility against Cefoperazone-Sulbactam (CS), imipenem and colistin in a tertiary care hospital in South India. Tigecycline showed 100% activity against E.coli, similar to colistin and better than impenem and cefoperazone-sulbactam. However only 80% of Klebsiella pneumoniae isolates remained susceptible to tigecycline and colistin had higher in vitro activity against Acinetobacter. Tigecycline is a good option for the management of MDR E.coli and an alternative option against Acinetobacter infections in India. However the decline in susceptibility of tigecycline against K.pneumoniae is a worrisome phenomenon.
© 2012 Dorairajan Sureshkumar, Ram Gopalakrishnan and M. A. Thirunarayan. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.